Biopharma
Samsung Biologics Q2 operating profit KRW 586.4 billion, up 23%
Panoramic view of Samsung Biologics headquarters. Courtesy of Samsung Biologics Samsung Biologics continued its solid growth momentum, supported by stable business operations and favorable foreign exchange effects.Samsung Biologics announced on the 23rd that it posted sales of KRW 1,320.9 billion an
2026.07.23